Lenalidomide: an immunomodulatory drug (Q36429554)

14 August 2017

1 reference

title

Lenalidomide: an immunomodulatory drug (English)

1 reference

14 August 2017

Edward Crane

1

1 reference

PubMed ID

16556034

14 August 2017

Alan List

series ordinal

2

1 reference

PubMed ID

16556034

14 August 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

14 August 2017

1 reference

14 August 2017

1

1 reference

14 August 2017

5

1 reference

14 August 2017

575-583

1 reference

The evolution of thalidomide and its IMiD derivatives as anticancer agents

14 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.5.575

Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.5.575

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.5.575

Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.5.575

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.5.575

Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.5.575

Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.5.575

A combination of flk1-based DNA vaccine and an immunomodulatory gene (IL-12) in the treatment of murine cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.5.575

Thalidomide in solid tumours: the resurrection of an old drug

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.5.575

Antiangiogenic therapy in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.5.575

Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.5.575

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.5.575

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.5.575

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.5.575

Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.5.575

Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.5.575

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.5.575

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.5.575

Thalidomid: current role in the treatment of non-plasma cell malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.5.575

Efficacy of lenalidomide in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.5.575

21 January 2018

Identifiers

DOI

10.2217/14796694.1.5.575

1 reference

14 August 2017

1 reference

PubMed ID

16556034